LT
Lucy To
Executive VP & CFOMs. Lucy To has been Chief Financial Officer of SAB Biotherapeutics, Inc. since July 26, 2024 and serves as its EVP since 2025. She was Managing Director of Healthcare Coverage Group for Corporate & Investment Banking at Wells Fargo & Company since October 2020. She joins Wells Fargo from Deutsche Bank, where she focused on healthcare investment banking coverage of biopharma companies. Prior to that, she worked in business development at Intercept Pharmaceuticals and in healthcare investment banking at Citigroup and Cowen. She received a B.A. in finance from Southern Methodist University.
Positions
- Company NameSAB Biotherapeutics, Inc.Stock CodeSABSPositionExecutive VP & CFOColleagues
- SJSamuel J. ReichCEO & Director
- DSDavid Scott ZaccardelliIndependent Chair of the Board
- EJEddie Joe SullivanCo-Founder, President & Director
- CBChristoph BauschExecutive VP & COO
- AKAlexandra KropotovaExecutive VP & Chief Medical Officer
- DCDavid Charles LinkIndependent Vice Chairman
- EJErick J. LuceraIndependent Director
